Newswire (Published: Monday, July 1, 2019, Received: Monday, July 1, 2019, 4:47:39 PM CDT)
Word Count: 599
2019 JUL 01 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Fresh data on Oncology - Prostate Cancer are presented in a new report. According to news reporting originating from New York City, United States, by NewsRx correspondents, research stated, “Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of this heterogeneity on clinical outcome. Here, we report comprehensive genomic and transcriptomic analysis of 429 patients with metastatic castration-resistant prostate cancer (mCRPC) linked with longitudinal clinical outcomes, integrating findings from whole-exome, transcriptome, and histologic analysis.”
Funders for this research include Prostate Cancer Foundation, Stand Up to Cancer Prostate Cancer Dream Team research grant, American Association for Cancer Research Award, Prostate Cancer Foundation Young Investigator Awards, Department of Defense Prostate Cancer Research Program, NCI Prostate Cancer SPORE Awards, NCI Cancer Center Award, NIH Award, European Research Council Consolidator Grant, Nuovo-Soldati Foundation, Movember Foundation, Prostate Cancer UK, ECMC network from Cancer Research UK, Department of Health in the UK, BRC, PCF.
Our news editors obtained a quote from the research from Cornell University, “For 128 patients treated with a first-line next-generation androgen receptor signaling inhibitor (ARSI; abiraterone or enzalutamide), we examined the association of 18 recurrent DNA-and RNA-based genomic alterations, including androgen receptor (AR) variant expression, AR transcriptional output, and neuroendocrine expression signatures, with clinical outcomes. Of these, only RB1 alteration was significantly associated with poor survival, whereas alterations in RB1, AR, and TP53 were associated with shorter time on treatment with an ARSI.”
According to the news editors, the research concluded: “This large analysis integrating mCRPC genomics with histology and clinical outcomes identifies RB1 genomic alteration as a potent predictor of poor outcome, and is a community resource for further interrogation of clinical and molecular associations.”
For more information on this research see: Genomic Correlates of Clinical Outcome In Advanced Prostate Cancer. Proceedings of the National Academy of Sciences, 2019;116(23):11428-11436. Proceedings of the National Academy of Sciences can be contacted at: Natl Acad Sciences, 2101 Constitution Ave NW, Washington, DC 20418, USA. (National Academy of Sciences - http://www.nasonline.org/; Proceedings of the National Academy of Sciences - http://www.nasonline.org/publications/pnas/)
The news editors report that additional information may be obtained by contacting M.A. Rubin, Cornell University, Dept. of Pathology, Weill Cornell Medical College, New York, NY 10021, United States. Additional authors for this research include W. Abida, H.I. Scher, P.W. Kantoff, J. Cyrta, A. Sboner, J.M. Mosquera, B.D. Robinson, M. Loda, G. Heller, N. Schultz, D. Prandi, M. Benelli, T. Fedrizzi, F. Demichelis, J. Armenia, C.L. Sawyers, I. Coleman, N. De Sarkar, C.C. Pritchard, R.B. Montgomery, P.S. Nelson, M. Cieslik, D. Robinson, L.P. Kunju, S. Tomlins, Y.M. Wu, A.M. Chinnaiyan, E.M. Van Allen, S. Carreira, P. Rescigno, H. Beltran, M.E. Taplin, D.N. Rodrigues, J. Mateo, D. Bianchini, S. Miranda, J.S. deBono, A. Gopalan, V.E. Reuter, J. Filipenko, J. Vinson and E.I. Heath.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1073/pnas.1902651116. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)
Prostate Cancer Uk
Cancer Research Uk
District of Columbia
New York City
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Politics and Government
Government Agencies (U.S.)
Department of Defense